期刊文献+

伴Ph染色体阳性的急性早幼粒细胞白血病诊治反思 被引量:5

Thinking in Diagnosis and Treatment of Acute Promyelocytic Leukemia with Philadelphia Chromosome Positivity
下载PDF
导出
摘要 目的探讨伴Ph染色体阳性急性早幼粒细胞白血病(acute promyelocytic leukemia,APL)的临床特征及诊治措施,以减少误诊误治。方法回顾性分析我院收治的1例骨髓形态、免疫组织化学及免疫表型极似急性粒单核细胞白血病且Ph染色体阳性APL的临床资料。结果本例因发热3周余就诊,根据骨髓形态学、免疫组织化学及免疫分型结果,初诊为急性粒单核细胞白血病,给予标准IDA方案(伊达比星加阿糖胞苷)化学治疗效果不佳。复查骨髓形态学并结合细胞遗传学检查,确诊为伴Ph染色体阳性APL,经维A酸(ATRA)联合三氧化二砷(ATO)治疗达完全缓解(CR),巩固治疗4个疗程。随访8个月仍处于CR,PML-RARA融合基因转阴,但BCR-ABL融合基因仍阳性。结论细胞遗传学检查应作为拟诊急性白血病患者的必要检查,可减少误诊,提高治疗效果。 Objective To explore the clinical features, diagnosis and treatment of acute promyelocytic leukemia ( APL) with philadelphia chromosome ( Ph) positivity in order to avoid misdiagnosis and mistreatment. Methods Clinical data of a patient with Ph-positive acute promyelocytic leukemia manifesting as acute myelomonocytic leukemia was retrospec-tively analyzed, and related literature was reviewed. Results The patient was admitted for fever over three weeks. Primary diagnosis was acute myelomonocytic leukemia after examinations of morphologic, immunophenotypic and histochemistry. But the standard IDA regimen was ineffective, which used idarubicin and cytarabine. APL with positive Ph was confirmed by cyto-genetics and morphologic studies. Complete remission was obtained after treatment with all-trans-retinoic acid ( ATRA) and arsenic trioxide ( ATO) . There was no evidence of recurrence for 8 months after 4 cycles of consolidation therapy. PML-RARA fusion gene was changed to be negative, but BCR-ABL fusion gene was still positive. Conclusion Cytogenetic examination for suspected acute leukemia patients is necessary to reduce misdiagnosis and improve the therapeutic effect.
出处 《临床误诊误治》 2014年第11期1-4,共4页 Clinical Misdiagnosis & Mistherapy
基金 上海市医学重点专科项目(ZK2012A26)
关键词 白血病 早幼粒细胞 急性 PH染色体阳性 误诊 白血病 粒单核细胞 急性 Leukemia,promyelocytic,acute,positive Philadelphia chromosome Diagnostic errors Leukemia,myelomonocytic,acute
  • 相关文献

参考文献12

  • 1周帆,李建勇,薛永权,邵景章,陈子兴,陆庭卫.形态学免疫学和细胞遗传学分型对急性白血病的诊断价值[J].上海医学,1997,20(12):713-714. 被引量:13
  • 2Lo Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia[ J]. N Engl J Med, 2013,369(2) :111-121.
  • 3Vardiman J W, Harris N L, Brunning R D. The World Health Organization (WHO) classification of the myeloid neoplasms [ J ]. Blood, 2002,100 ( 7 ) :2292-2302.
  • 4Tallman M S, Altman J K. How I treat acute promyelo- cytic leukemia [ J]. Blood, 2009,114 (25) :5126-5135.
  • 5de Th6 H, Chen Z. Acute promyelocytic leukaemia: no- vel insights into the mechanisms of cure [ J ]. Nat Rev Cancer, 2010, I0( 11 ) :775-783.
  • 6Lo Coco F, Avvisati G, Orlando S M, et al. ATRA and arsenic trioxide (ATO) versus ATRA and idarubicin (AI- DA) for newly diagnosed, non high-risk acute promyelo- cytie leukemia (APL) : results of the phase III, prospec- tive, randomized, intergroup APL0406 study by the Ital- ian-German cooperative groups GIMEMA-SAL-AMLSG [ J ]. Blood, 2012,120 ( Suppl 1 ) : Abstract 6.
  • 7Iland H J, Bradstock K, Supple S G, et al. All-trans-ret- inoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4) [ J ]. Blood, 2012,120(8) :1570-1580.
  • 8de Botton S, Chevret S, Sanz M, et al. Additional chro- mosomal abnormalities in patients with acute promyelocyt- ic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial[ J ]. Br J Haematol, 2000,111 ( 3 ) : 801- 806.
  • 9Cervera J, Montesinos P, Hernandez Rivas J M, et al. Additional chromosomal abnormalities in patients with a- cute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy [J]. Haematoloica, 2010, 95 (3) :424-431.
  • 10Mao L, Wang H, Cheng Y, et al. Occurrence of t( 15; 17) (q22;q21) and t(9;22) (q34;qll) in a patient with acute promyelocytic leukemia [ J ]. Leuk Lymphoma, 2009,50 (3) :466-470.

二级参考文献2

共引文献12

同被引文献43

引证文献5

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部